(MENAFN- America News Hour)
Research Nester released a report titled “Gene Modifying Immunotherapy for Blood Cancer Market: Global Demand Analysis & Opportunity Outlook 2027” which delivers detailed overview of the global gene modifying immunotherapy for blood cancer market in terms of market segmentation by therapy, by blood cancer, by end user and by region.
Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter's five force model.
The gene modifying immunotherapy for blood cancer market is estimated to observe a significant CAGR during the forecast period, i.e., 2019-2027 as a result of growing research and development activities by various institutions and organizations. The market is segmented by therapy, by blood cancer, by end user and by region, out of which, the therapy segment is further bifurcated into CAR T-cell therapy and TCR T-cell therapy. Based on therapy, the CAR T-cell therapy segment is estimated to observe the highest growth during the forecast period which can be attributed to the rising demand for this therapy as well as the high efficacy of this form of cancer immunotherapy.
The growth of this market is anticipated to be the highest in the North America region during the forecast period. The rising cases of blood cancer in the region is one of the leading factors leading to the demand for immunotherapy involving gene modification. Moreover, the advancements in medical technology and demand for better cancer treatment methods are further estimated to boost the market growth. The market in Asia-Pacific region is anticipated to grow at a significant rate on account of high demand for CAR T-cell therapy, mainly in countries such as China and India.
The Final Report will cover the impact analysis of COVID-19 on this industry@
Growing Prevalence of Blood Cancer to Drive the Growth of the Market
Recent surveys and statistics have found that blood cancer cases are rising all over the world and thus resulting in the demand for effective therapies for adults as well as for children. For instance, the National Cancer Institute reported that around 61,780 new cases of leukemia are estimated to occur by the end of 2019 in the United States. According to the statistics, this is anticipated to account for 3.5% of all cancer cases in the country for the year. This is a major growth driver estimated to facilitate the market growth. On the other hand, the various side effects of gene modifying immunotherapy such as cytokine release syndrome in case of CAR T-cell therapy are anticipated to hamper the growth of this market in the upcoming years.
This report also provides the existing competitive scenario of some of the key players of the global gene modifying immunotherapy for blood cancer market which includes company profiling of Novartis AG (NOVN), Kite Pharma, Juno Therapeutics, Cellectis (ALCLS), Ziopharm Oncology (ZIOP), Celyad (CYAD), Bluebird Bio (BLUE), Bellicum Pharmaceuticals (BLCM), Mustang Bio (MBIO) and Johnson & Johnson Services. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global gene modifying immunotherapy for blood cancer market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.
Download Sample Report@
About Research Nester
Research Nester is a one-stop service provider, leading in strategic market research and consulting with an unbiased and unparalleled approach towards helping global industrial players, conglomerates and executives to make wise decisions for their future investment and expansion by providing them qualitative market insights and strategies while avoiding future uncertainties. We believe in honesty and sheer hard work that we trust is reflected in our work ethics. Our vision is not just limited to gain the trust of our clients but also to be equally respected by our employees and being appreciated by the competitors.
MENAFN27072022004545010068ID1104603430
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.